Skip to content

A Clinical trial to study the efficacy and safety of prednisolone in limb girdle muscle dystrophy type 2A and 2B

Efficacy and Safety of Oral Prednisolone in Limb Girdle Muscular Dystrophy: A Randomized Double Blinded Placebo Controlled Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031000
Enrollment
80
Registered
2021-02-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G710- Muscular dystrophy

Interventions

Intervention1: Prednisolone: prednisolone initial doses of 0.75 mg per kg per day with a maximum dose of 60 mg per day for initial 6 weeks duration, Following 6 weeks if patient is receiving more tha

Sponsors

Dr P Sathish
Lead Sponsor
Dr Rohit Bhatia
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients with immunohistochemical, immunoblot and genetically confirmed cases of calpainopathy LGMD2A, dysferlinopathy LGMD2B will be included in the trial. 2)Symptom onset less than 5 years 3)Medical Research Council (MRC) grade power of greater than or equal to 3/5 4)Able to stand on own, turn in bed, walk alone, eat and drink

Exclusion criteria

Exclusion criteria: 1)Obesity (BMI of 30 or above) 2)Diabetes Mellitus 3)Hypertension 4)Active infection on screening 5)Active TB 6)Retroviral illness 7)Any h/o melena, hematemesis, history of peptic ulcer disease 8)Chronic obstructive pulmonary disease (COPD). 9)Known cardiac failure and EF (ejection fraction) 10)Currently taking steroids for any other indication 11)Currently taking immunosuppressive therapy 12)Any immunosuppressive treatment till 2 months prior to screening period 13)Any condition in the understanding of investigator not ideal for usage of steroids 14)Pregnant and lactating mother 15)Patients on drugs that are known to improve muscle function such as CoQ, carnitine supplements etc.

Design outcomes

Primary

MeasureTime frame
1)Time taken to get up from supine to standing position from baseline to at the end of 6 weeks 2)Time taken to climb flight of four stairs from baseline to at the end of 6 weeks. 3)Amount of distance covered in 6 min walk test from the baseline to at the end of 6 weeks Timepoint: At the end of 6 weeks

Secondary

MeasureTime frame
1)MRC Grade of selected muscle groups 2)Quality of life QOL assessment by SF-36 questionnaire 3)MR imaging of muscle to assess for inflammatory change Timepoint: At the end of 6 weeks

Countries

India

Contacts

Public ContactDr Rohit Bhatia

All India Institute Of Medical Sciences(AIIMS) New Delhi

rohitbhatia71@yahoo.com9891267417

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026